Printer Friendly

Articles from China Biotech (April 10, 2019)

1-22 out of 22 article(s)
Title Author Type Words
Amoytop Biotech. 221
Beijing Peking University WBL Biotech Co., Ltd. (WPU). 1220
Beijing Tri-Prime Genetic Engineering Co., Ltd. 250
China National Biotec Group (HKSE: CNBG). 199
China Shineway Pharmaceutical Group Limited (HKSE: 2877). 252
Chindex International, Inc. (NASDAQ: CHDX). 820
Livzon Mabpharm. 243
Mindray Medical International Limited (NYSE: MR). 282
SciClone Pharmaceuticals, Inc (NASDAQ: SCLN). 1280
Shanghai ChemPartner Co Ltd (NYSE: SHP). 446
ShangPharma Corporation. 120
SiBiono Gene-Tech Co. Ltd (SSGTCZ). 226
Simcere Pharmaceutical Group (NYSE: SCR). 3742
Sinovac Biotech Ltd. (NASDAQ: SVA) - Sinovac Update on the Exchange of Rights for Common and Series B Preferred Shares -- 9/3/2019. 307
Sinovac Biotech Ltd. (NASDAQ: SVA). 1226
The Industry. 752
Winteam Pharmaceutical Group Limited (HKSE: 570). 2225
WuXi AppTec Testing Facilities Complete Three Regulatory Inspections from US FDA, OECD, and CNAS with Excellent Results -- 11/3/2019. 347
WuXi PharmaTech (NYSE: WX) - WuXi AppTec Appoints Dr. Frederick H. Hausheer as Chief Medical Officer -- 8/4/2019. 451
WuXi PharmaTech (NYSE: WX) - WuXi AppTec Reports Strong 2018 Annual Results -- 22/3/2019. Financial report 659
WuXi PharmaTech (NYSE: WX) -WuXi STA's New Drug Product Manufacturing Facility Passes First European MPA GMP Inspection -- 27/3/2019. 356
WuXi PharmaTech (NYSE: WX). 659

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters |